Upshaw-Schulman syndrome revisited: A concept of congenital thrombotic thrombocytopenic purpura

被引:99
作者
Kinoshita, S
Yoshioka, A
Park, YD
Ishizashi, H
Konno, M
Funato, M
Matsui, T
Titani, K
Yagi, H
Matsumoto, M
Fujimura, Y
机构
[1] Nara Med Univ, Dept Blood Transfus Med, Kashihara, Nara 6348522, Japan
[2] Nara Med Univ, Dept Pediat, Kashihara, Nara 6348522, Japan
[3] Nara Med Univ, Dept Hlth Sci, Kashihara, Nara 6348522, Japan
[4] Sapporo Kosei Gen Hosp, Dept Pediat, Sapporo, Hokkaido, Japan
[5] Yodogawa Christian Hosp, Dept Pediat, Osaka, Japan
[6] Fujita Hlth Univ, Inst Comprehens Med Sci, Aichi, Japan
关键词
Upshaw-Schulman syndrome; chronic relapsing TTP; von Willebrand factor-cleaving protease; fresh frozen plasma;
D O I
10.1007/BF02982558
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Upshaw-Schulman syndrome (USS) is a congenital bleeding disorder characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respond to infusions of fresh frozen plasma. Inheritance of USS has been thought to be autosomal recessive, because 2 siblings in the same family are often affected but their parents are asymptomatic. Recently, chronic relapsing thrombotic thrombocytopenic purpura (CR-TTP), reported almost exclusively in adults, was shown to be caused by inherited or acquired deficiency in the activity of a plasma von Willebrand factor-cleaving protease (vWF-CPase). The pathogenesis of USS is unknown, and a relationship between CR-TTP and USS has not been reported. We studied 3 unrelated USS patients (ST, SY, and KI) who presented with severe indirect neonatal hyperbilirubimenia. All 3 patients had undetectable vWF-CPase activity, and the inhibitors to vWF-CPase were all negative. In their parents with no clinical symptoms, vWF-CPase activities as a percentage of control samples (mother/father) were 17/20 for ST, 60/45 for SY, and 36/5.6 for KI. Thus, USS and vWF-CPase activity appear to be coinherited as autosomal recessive traits. Transfusion of fresh frozen plasma in 2 patients (ST and SY) resulted in the expected maximal increment of approximately 7% to 8% in vWF-CPase activity at 1 to 4 hours, but the levels became less than 3% within 2 days. After this decrease, platelet counts increased, plateaued in the normal range at 10 to 12 days, and declined thereafter. Thus, the 2 to 3 weeks of therapeutic benefit from plasma infusions will be discussed in relation to the intravascular lifetime of vWF-CPase. (C) 2001 The Japanese Society of Hematology.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 26 条
[1]  
BUDDE U, 1990, THROMB HAEMOSTASIS, V63, P312
[2]  
FUJIMURA Y, 1986, J BIOL CHEM, V261, P381
[3]  
Furlan M, 1999, THROMB HAEMOSTASIS, V81, P8
[4]   Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura [J].
Furlan, M ;
Robles, R ;
Solenthaler, M ;
Wassmer, M ;
Sandoz, P ;
Lammle, B .
BLOOD, 1997, 89 (09) :3097-3103
[5]   Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].
Furlan, M ;
Robles, R ;
Galbusera, M ;
Remuzzi, G ;
Kyrle, PA ;
Brenner, B ;
Krause, M ;
Scharrer, I ;
Aumann, V ;
Mittler, U ;
Solenthaler, M ;
Lämmle, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1578-1584
[6]   Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis [J].
Furlan, M ;
Robles, R ;
Lammle, B .
BLOOD, 1996, 87 (10) :4223-4234
[7]  
GOODNOUGH LT, 1982, NEW ENGL J MED, V306, P938
[8]  
HARA T, 1986, AM J PEDIAT HEMATOL, V8, P324
[9]  
KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869
[10]  
KOIZUMI S, 1981, NEW ENGL J MED, V305, P1284